Monogenic Diabetes Panel
Use
This test is intended for individuals with relevant features who have a clinical or suspected diagnosis of monogenic diabetes. It is specifically for individuals diagnosed with diabetes before age 25 with continued endogenous insulin production or those diagnosed within the first 6 months of life. Early-onset diabetes (before age 40) previously diagnosed as type 1/type 2 is also considered for this testing.
Special Instructions
Not provided.
Limitations
Tests have not been cleared or approved by the US Food and Drug Administration. Made per CAP and CLIA regulations by PreventionGenetics in Marshfield, Wisconsin. Analytical or technical constraints are not detailed, and clinical interpretation accuracy correlates with the quality of clinical information provided by the healthcare provider.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided